Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

Mouse models of human AML accurately predict chemotherapy response.

Zuber J, Radtke I, Pardee TS, Zhao Z, Rappaport AR, Luo W, McCurrach ME, Yang MM, Dolan ME, Kogan SC, Downing JR, Lowe SW.

Genes Dev. 2009 Apr 1;23(7):877-89. doi: 10.1101/gad.1771409.

2.

AML1-ETO triggers epigenetic activation of early growth response gene l, inducing apoptosis in t(8;21) acute myeloid leukemia.

Fu L, Huang W, Jing Y, Jiang M, Zhao Y, Shi J, Huang S, Xue X, Zhang Q, Tang J, Dou L, Wang L, Nervi C, Li Y, Yu L.

FEBS J. 2014 Feb;281(4):1123-31. doi: 10.1111/febs.12673. Epub 2014 Jan 10.

3.

Monitoring the AML1/ETO fusion transcript to predict outcome in childhood acute myeloid leukemia.

Zhang L, Cao Z, Ruan M, Zeng Q, Zhao L, Li Q, Zou Y, Wang J, Zhu X.

Pediatr Blood Cancer. 2014 Oct;61(10):1761-6. doi: 10.1002/pbc.25109. Epub 2014 Jun 11.

PMID:
24920269
4.

KRAS (G12D) cooperates with AML1/ETO to initiate a mouse model mimicking human acute myeloid leukemia.

Zhao S, Zhang Y, Sha K, Tang Q, Yang X, Yu C, Liu Z, Sun W, Cai L, Xu C, Cui S.

Cell Physiol Biochem. 2014;33(1):78-87. doi: 10.1159/000356651. Epub 2014 Jan 17.

5.

Translocation products in acute myeloid leukemia activate the Wnt signaling pathway in hematopoietic cells.

Müller-Tidow C, Steffen B, Cauvet T, Tickenbrock L, Ji P, Diederichs S, Sargin B, Köhler G, Stelljes M, Puccetti E, Ruthardt M, deVos S, Hiebert SW, Koeffler HP, Berdel WE, Serve H.

Mol Cell Biol. 2004 Apr;24(7):2890-904.

6.

AML1-ETO driven acute leukemia: insights into pathogenesis and potential therapeutic approaches.

Hatlen MA, Wang L, Nimer SD.

Front Med. 2012 Sep;6(3):248-62. doi: 10.1007/s11684-012-0206-6. Epub 2012 Aug 9. Review.

PMID:
22875638
7.

The AML1-ETO fusion gene and the FLT3 length mutation collaborate in inducing acute leukemia in mice.

Schessl C, Rawat VP, Cusan M, Deshpande A, Kohl TM, Rosten PM, Spiekermann K, Humphries RK, Schnittger S, Kern W, Hiddemann W, Quintanilla-Martinez L, Bohlander SK, Feuring-Buske M, Buske C.

J Clin Invest. 2005 Aug;115(8):2159-68. Epub 2005 Jul 14.

8.

Clinical significance of lymphoid enhancer-binding factor 1 expression in acute myeloid leukemia.

Fu Y, Zhu H, Wu W, Xu J, Chen T, Xu B, Qian S, Li J, Liu P.

Leuk Lymphoma. 2014 Feb;55(2):371-7. doi: 10.3109/10428194.2013.805759. Epub 2013 Jul 8.

PMID:
23713453
9.

High expression of c-kit mRNA predicts unfavorable outcome in adult patients with t(8;21) acute myeloid leukemia.

Gao X, Lin J, Gao L, Deng A, Lu X, Li Y, Wang L, Yu L.

PLoS One. 2015 Apr 10;10(4):e0124241. doi: 10.1371/journal.pone.0124241. eCollection 2015.

10.

EVI1 is critical for the pathogenesis of a subset of MLL-AF9-rearranged AMLs.

Bindels EM, Havermans M, Lugthart S, Erpelinck C, Wocjtowicz E, Krivtsov AV, Rombouts E, Armstrong SA, Taskesen E, Haanstra JR, Beverloo HB, Döhner H, Hudson WA, Kersey JH, Delwel R, Kumar AR.

Blood. 2012 Jun 14;119(24):5838-49. doi: 10.1182/blood-2011-11-393827. Epub 2012 May 2.

11.

Overexpression of MN1 confers resistance to chemotherapy, accelerates leukemia onset, and suppresses p53 and Bim induction.

Pardee TS.

PLoS One. 2012;7(8):e43185. doi: 10.1371/journal.pone.0043185. Epub 2012 Aug 14.

12.

AML1-ETO rapidly induces acute myeloblastic leukemia in cooperation with the Wilms tumor gene, WT1.

Nishida S, Hosen N, Shirakata T, Kanato K, Yanagihara M, Nakatsuka S, Hoshida Y, Nakazawa T, Harada Y, Tatsumi N, Tsuboi A, Kawakami M, Oka Y, Oji Y, Aozasa K, Kawase I, Sugiyama H.

Blood. 2006 Apr 15;107(8):3303-12. Epub 2005 Dec 27.

13.

Differentiation therapy for the treatment of t(8;21) acute myeloid leukemia using histone deacetylase inhibitors.

Bots M, Verbrugge I, Martin BP, Salmon JM, Ghisi M, Baker A, Stanley K, Shortt J, Ossenkoppele GJ, Zuber J, Rappaport AR, Atadja P, Lowe SW, Johnstone RW.

Blood. 2014 Feb 27;123(9):1341-52. doi: 10.1182/blood-2013-03-488114. Epub 2014 Jan 10.

14.

Cell of origin determines clinically relevant subtypes of MLL-rearranged AML.

Krivtsov AV, Figueroa ME, Sinha AU, Stubbs MC, Feng Z, Valk PJ, Delwel R, Döhner K, Bullinger L, Kung AL, Melnick AM, Armstrong SA.

Leukemia. 2013 Apr;27(4):852-60. doi: 10.1038/leu.2012.363. Epub 2012 Dec 13.

15.

A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis.

Yan M, Kanbe E, Peterson LF, Boyapati A, Miao Y, Wang Y, Chen IM, Chen Z, Rowley JD, Willman CL, Zhang DE.

Nat Med. 2006 Aug;12(8):945-9. Epub 2006 Jul 30.

PMID:
16892037
16.

Comprehensive analysis of cooperative gene mutations between class I and class II in de novo acute myeloid leukemia.

Ishikawa Y, Kiyoi H, Tsujimura A, Miyawaki S, Miyazaki Y, Kuriyama K, Tomonaga M, Naoe T.

Eur J Haematol. 2009 Aug;83(2):90-8. doi: 10.1111/j.1600-0609.2009.01261.x. Epub 2009 Mar 21.

PMID:
19309322
17.

Rapid detection of AML1 associated fusion genes in patients with adult acute myeloid leukemia and its clinical significance.

Jiang MM, Gao L, Jing Y, Ding Y, Xu YY, Zhou MH, Ma C, Wang N, Wang W, Han XP, Li HH, Wang QS, Wang LL, Yu L.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2013 Aug;21(4):821-9. doi: 10.7534/j.issn.1009-2137.2013.04.002.

PMID:
23998567
18.

The AML1 gene: a transcription factor involved in the pathogenesis of myeloid and lymphoid leukemias.

Lo Coco F, Pisegna S, Diverio D.

Haematologica. 1997 May-Jun;82(3):364-70. Review.

19.

The t(8;21) fusion protein, AML1 ETO, specifically represses the transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia.

Linggi B, Müller-Tidow C, van de Locht L, Hu M, Nip J, Serve H, Berdel WE, van der Reijden B, Quelle DE, Rowley JD, Cleveland J, Jansen JH, Pandolfi PP, Hiebert SW.

Nat Med. 2002 Jul;8(7):743-50. Epub 2002 Jun 24.

PMID:
12091906
20.

Targeting of AML1-ETO in t(8;21) leukemia by oridonin generates a tumor suppressor-like protein.

Zhen T, Wu CF, Liu P, Wu HY, Zhou GB, Lu Y, Liu JX, Liang Y, Li KK, Wang YY, Xie YY, He MM, Cao HM, Zhang WN, Chen LM, Petrie K, Chen SJ, Chen Z.

Sci Transl Med. 2012 Mar 28;4(127):127ra38. doi: 10.1126/scitranslmed.3003562.

Supplemental Content

Support Center